Stock Events

Stock Events

Abivax 

$139.08
138
-$1.66-1.18% 13:34 Today

Statistics

Day High
140.74
Day Low
139.08
52W High
145.31
52W Low
7.75
Volume
97,168
Avg. Volume
-
Mkt Cap
11.09B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

21SepExpected
Q2 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-2.46
-1.88
-1.29
-0.7
Expected EPS
-0.958702267
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-367.82MNet Income

Analyst Ratings

154.22Average Price Target
The highest estimate is 187.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
78%
Hold
22%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABVX. It's not an investment recommendation.
TotalEnergies
25
TTE.PA
Air Liquide
25
AI.PA
NVIDIA
21
NVDA
Microsoft
19
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences is a biopharmaceutical company that competes with Abivax in the development of antiviral drugs, including treatments for HIV, which is a focus area for Abivax.
Vertex Pharmaceuticals
VRTX
Mkt Cap134.02B
Vertex Pharmaceuticals is involved in creating antiviral treatments and therapies for infectious diseases, competing directly with Abivax's efforts in HIV and other viral infections.
Merck
MRK
Mkt Cap319.99B
Merck & Co., Inc. is a global healthcare company that develops antiviral drugs, including therapies for HIV/AIDS, positioning it as a competitor to Abivax.
GSK
GSK
Mkt Cap107.47B
GlaxoSmithKline plc focuses on developing and marketing vaccines and medications for HIV, directly competing with Abivax's research and development in HIV treatments.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its pharmaceutical division Janssen, works on developing treatments for infectious diseases, including HIV, making it a competitor to Abivax.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie Inc. competes in the area of antiviral research, with a focus on therapies for HIV, hepatitis, and other viral infections, areas that Abivax is also targeting.
Pfizer
PFE
Mkt Cap138.61B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products, including antiviral drugs, competing with Abivax in the infectious disease space.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol Myers Squibb is engaged in the discovery and development of prescription medicines for various diseases, including HIV/AIDS, making it a direct competitor to Abivax.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals, Inc. is known for its work in biotechnology and the development of medicines for infectious diseases, competing with Abivax in the biopharmaceutical field.
Novartis
NVS
Mkt Cap305.1B
Novartis AG is a global healthcare company that researches and develops treatments for a wide range of diseases, including viral infections, competing with Abivax in the pharmaceutical and healthcare market.

About

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Show more...
CEO
Mr. Marc M. P. de Garidel M.B.A.
Employees
69
Country
France
ISIN
US00370M1036

Listings

F
DE
2X10.F
STU
DE
2X10.STU
XETRA
DE
2X1.XETRA
STU
DE
2X1.STU

0 Comments

Share your thoughts

FAQ

What is Abivax stock price today?▼
The current price of ABVX is $139.08 USD — it has decreased by -1.18% in the past 24 hours. Watch Abivax stock price performance more closely on the chart.
What is Abivax stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Abivax stocks are traded under the ticker ABVX.
Is Abivax stock price growing?▼
ABVX stock has fallen by -2.7% compared to the previous week, the month change is a +43.57% rise, over the last year Abivax has showed a +1,595.66% increase.
What is Abivax market cap?▼
Today Abivax has the market capitalization of 11.09B
When is the next Abivax earnings date?▼
Abivax is going to release the next earnings report on September 21, 2026.
What were Abivax earnings last quarter?▼
ABVX earnings for the last quarter are -0.7 USD per share, whereas the estimation was -0.93 USD resulting in a +24.01% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Abivax revenue for the last year?▼
Abivax revenue for the last year amounts to 0 USD.
What is Abivax net income for the last year?▼
ABVX net income for the last year is -367.82M USD.
How many employees does Abivax have?▼
As of July 10, 2026, the company has 69 employees.
In which sector is Abivax located?▼
Abivax operates in the Health & Wellness sector.
When did Abivax complete a stock split?▼
Abivax has not had any recent stock splits.
Where is Abivax headquartered?▼
Abivax is headquartered in Paris, France.